

DAFTAR PUSTAKA

- Akdogan, M.R. and Melikoglu, M.A. (2024) 'A potential biomarker of disease activity in systemic lupus erythematosus, systemic immune-inflammation index', *Northern Clinics of Istanbul*, 11(2), pp. 115–119. Accessed on: <https://doi.org/10.14744/NCI.2023.90132>.
- Al-Hamadani, M. et al. (2025) "Chloroquine and hydroxychloroquine: Immunomodulatory effects in autoimmune diseases," *World Journal of Biological Chemistry*, 16(2), pp. 1–14. Available at: <https://doi.org/10.4331/wjbc.v16.i2.107042>.
- Alves, P. et al. (2021) 'Validation of a machine learning approach to estimate Systemic Lupus Erythematosus Disease Activity Index score categories and application in a real-world dataset', *RMD Open*, 7(2). Accessed on: <https://doi.org/10.1136/rmdopen-2021-001586>.
- Amelia, R., Wasilah, F. and Suraya, N. (2024) 'Correlation of Platelet to Lymphocyte Ratio and C-Reactive Protein to Albumin Ratio with MEX-SLEDAI Scores in Patients with Systemic Lupus Erythematosus', *Althea Medical Journal*, 11(3), pp. 183–187. doi:10.15850/amj.v11n3.3255.
- Angum, F. et al. (2020) "The Prevalence of Autoimmune Disorders in Women: A Narrative Review," *Cureus*, 12(5). Available at: <https://doi.org/10.7759/cureus.8094>.
- Aringer, M. et al. (2019) '2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus', *Arthritis and Rheumatology*, 71(9), pp. 1400–1412. Accessed on: <https://doi.org/10.1002/art.40930>.
- Barber, M.R.W. et al. (2021) 'Global epidemiology of systemic lupus erythematosus', *Nature Reviews Rheumatology*, 17(9), pp. 515–532. Accessed on: <https://doi.org/10.1038/s41584-021-00668-1>.
- Camins-Fàbregas, J. et al. (2019) "Ab0497 Serum Calprotectin in Systemic Lupus Erythematosus: Is It a Good Activity Biomarker?," *Annals of the Rheumatic Diseases*, 78, pp. 1711–1712. Available at: <https://doi.org/10.1136/annrheumdis-2019-eular.2295>.
- Carnazzo, V. et al. (2024) 'Calprotectin : two sides of the same coin', (August 2023), pp. 26–33.
- Crow, M.K. (2023) 'Pathogenesis of systemic lupus erythematosus: Risks, mechanisms and therapeutic targets', *Annals of the Rheumatic Diseases*. BMJ Publishing Group, pp. 999–1014. Accessed on : <https://doi.org/10.1136/ard-2022-223741>.
- Elsaeed, A.E.A., Salim, H.A.A., El-shafie, M.K., Maklad, A.M., El-Sayed, A.M. and Mousa, S.M. (2025) 'Serum Calprotectin Level in Patients with Systemic Lupus Erythematosus and its Correlation with Disease Activity', *The Medical Journal of Cairo University*, 93(September), pp. 289–297. doi:10.21608/mjcu.2025.464224.
- Fanouriakis, A. et al. (2021) 'Update in the diagnosis and management of systemic lupus erythematosus', *Annals of the Rheumatic Diseases*, 80(1), pp. 14–25. Accessed on: <https://doi.org/10.1136/annrheumdis-2020-218272>.
- Fatoye, F., Gebrye, T. and Mbada, C. (2022) "Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis," *Rheumatology International*, 42(12), pp. 2097–2107. Available at: <https://doi.org/10.1007/s00296-022-05183-4>.
- Gambichler, T., Numanovic, Z., Apel, I., Hessam, S., Susok, L., Baraliakos, X. and Sewerin, P. (2024) 'Do

novel inflammation biomarkers arising from routine complete blood count play a role in patients with systemic lupus erythematosus?', *Lupus*, 33(14). doi:10.1177/09612033241295865.

Gui, Y. *et al.* (2022) "Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII," *Chinese Medical Journal*, 135(18), pp. 2191–2199. Available at: <https://doi.org/10.1097/CM9.0000000000002360>.

Hamijoyo, L. *et al.* (2021) *Pedoman Diagnosis dan Pengelolaan LES, Indonesian Rheumatology Association*. Available at: <https://reumatologi.or.id/rekomendasi-osteoarthritis/>.

Homa-Mlak, I. *et al.* (2022) 'Serum Calprotectin - a NET Product - as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland', *Medical Science Monitor*, 28, pp. 1–10. Accessed on: <https://doi.org/10.12659/MSM.936534>.

Inciarte-Mundo, J., Frade-Sosa, B. and Sanmartí, R. (2022) 'From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis', *Frontiers in Immunology*, 13(November), pp. 1–13. Accessed on: <https://doi.org/10.3389/fimmu.2022.1001025>.

Lamot, M., Miler, M., Nikolac Gabaj, N., Lamot, L., Milošević, M., Harjaček, M. and Abdović, S. (2022) 'Serum Calprotectin Is a Valid Biomarker in Distinction of Bacterial Urinary Tract Infection From Viral Respiratory Illness in Children Under 3 Years of Age', *Frontiers in Pediatrics*, 10, p. 768260. doi:10.3389/fped.2022.768260.

Lee, Y.H. and Song, G.G. (2025) 'Systemic immune-inflammation index and systemic inflammation response index in systemic lupus erythematosus: a meta-analysis', *Zeitschrift für Rheumatologie*. doi:10.1007/s00393-025-01751-8.

Lin, A., Wakhlu, A. and Connelly, K. (2024) "Disease activity assessment in systemic lupus erythematosus," *Frontiers in Lupus*, 2(August). Available at: <https://doi.org/10.3389/flupu.2024.1442013>.

Lood, C. *et al.* (2011) 'Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus', *Arthritis Research and Therapy*, 13(2), p. R60. Accessed on: <https://doi.org/10.1186/ar3314>.

Marasović-Krstulović, D., Vrkić, K., Oreb, J., Petrić, M., Milovac, L. and Perković, D. (2024) 'P16 Serum calprotectin levels in patients with systemic lupus erythematosus and association with disease activity – single centre study', *Lupus Science & Medicine*, 11(Suppl 1), pp. A53–A54. doi:10.1136/lupus-2024-el.70.

Mokbel, A. *et al.* (2025) 'Disease activity at the onset of diagnosis as a predictor of disease outcomes in a cohort of patients with systemic lupus erythematosus: A post hoc retrospective analysis of the COMOSLE - EGYPT study', *Clinical Rheumatology*, 44(1), pp. 229–235. Accessed on: <https://doi.org/10.1007/s10067-024-07222-w>.

Nurbaeva, K. *et al.* (2026) "PO:02:043 Comparative utility of NLR and SII as biomarkers of disease activity in systemic lupus erythematosus," in *Posters*. Lupus Foundation of America, p. A109.2-A109. Available at: <https://doi.org/10.1136/lupus-2026-el.119>.

Nusbaum, J.S. *et al.* (2020) "Sex Differences in Systemic Lupus Erythematosus: Epidemiology, Clinical Considerations, and Disease Pathogenesis," *Mayo Clinic Proceedings*, 95(2), pp. 384–394. Available at: <https://doi.org/10.1016/j.mayocp.2019.09.012>.

Ocejo, A. and Correa, R. (2026) *Methylprednisolone*, *StatPearls*. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK544340/%0A>.

Ozdemir, A. *et al.* (2022) "Could systemic immune inflammation index be a new parameter for diagnosis and disease activity assessment in systemic lupus erythematosus?," *International Urology and Nephrology*, 55(1), pp. 211–216. Available at: <https://doi.org/10.1007/s11255-022-03320-3>.

Peng-Cheng, L. *et al.* (2024) "Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus," *Heliyon*, 10(9), p. e30393. Available at: <https://doi.org/10.1016/j.heliyon.2024.e30393>.

Perhimpunan Reumatologi Indonesia (2019) *Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik*, Perhimpunan Reumatologi Indonesia

Rhodes, B. and Vyse, T.J. (2012) "Systemic Lupus Erythematosus," *Genomic and Personalized Medicine*, pp. 970–982. Available at: <https://doi.org/10.1016/B978-0-12-382227-7.00080-X>.

Ronchetti, S. *et al.* (2018) "How glucocorticoids affect the neutrophil life," *International Journal of Molecular Sciences*, 19(12). Available at: <https://doi.org/10.3390/ijms19124090>.

Schrezenmeier, E. and Dörner, T. (2020) "Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology," *Nature Reviews Rheumatology*, 16(3), pp. 155–166. Available at: <https://doi.org/10.1038/s41584-020-0372-x>.

Su, X. *et al.* (2024) 'Systemic lupus erythematosus: pathogenesis and targeted therapy', *Molecular Biomedicine*, 5(1). Accessed on: <https://doi.org/10.1186/s43556-024-00217-8>.

Suszek, D. *et al.* (2024) 'Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) Usefulness in daily practice of the Systemic Lupus Erythematosus Disease Activity Index 2000 scale and the Systemic Lupus Erythematosus Disease Activity Score index for assessing the activity of systemic lupus erythematosus', *Reumatologia*, 62, pp. 187–195. Accessed on t: <https://doi.org/10.5114/reum.2024.141291>.

Thanou, A. *et al.* (2021) 'Clinical disease activity and flare in SLE: Current concepts and novel biomarkers', *Journal of Autoimmunity*. Academic Press. Accessed on: <https://doi.org/10.1016/j.jaut.2021.102615>.

Tjan, B., Kambayana, G. and Kurniari, P.K. (2022) 'Gambaran profil systemic lupus erythematosus (SLE) dan lupus nefritis di Rumah Sakit Umum Pusat Sanglah', *Jurnal Penyakit Dalam Udayana*, 6(2), pp. 31–35. Accessed on: <https://doi.org/10.36216/jpd.v6i2.187>.

Tian, J. *et al.* (2023) "Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study," *Annals of the Rheumatic Diseases*, 82(3), pp. 351–356. Available at: <https://doi.org/10.1136/ard-2022-223035>.

Ulung, Ismirawati and Nurulita, A. (2025) 'Systemic immune-inflammation index as a marker for septic patients', *Critical Care and Shock*, 28(1), pp. 9–16.

Vaillant, A.A.J. and Goyal, A. (2023) *Systemic lupus erythematosus: Continuing education activity*. Treasure Island (FL): StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK535405/>

Wakiya, R. *et al.* (2019) "Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus," *Lupus*, 28(7), pp. 826–833. Available at: <https://doi.org/10.1177/0961203319846391>.

Wakiya, R. *et al.* (2022) "Effect of add-on hydroxychloroquine therapy on serum proinflammatory cytokine levels in patients with systemic lupus erythematosus," *Scientific Reports*, 12(1), pp. 1–7. Available at: <https://doi.org/10.1038/s41598-022-14571-6>.

Wu, Yang *et al.* (2025) "Systemic immune-inflammation index as a versatile biomarker in autoimmune disorders: insights from rheumatoid arthritis, lupus, and spondyloarthritis," *Frontiers in Immunology*, 16(August), pp. 1–10. Available at: <https://doi.org/10.3389/fimmu.2025.1621209>.

Yang, C.H. *et al.* (2025) 'SIRI and SII as potential biomarkers of disease activity and lupus nephritis in systemic lupus erythematosus', *Frontiers in Immunology*, 16(January), pp. 1–10. Accessed on: <https://doi.org/10.3389/fimmu.2025.1530534>.

Yontar, G. and Mutlu, E.A. (2024) 'Neutrophil-to-lymphocyte, platelet-to-lymphocyte ratios and systemic immune-inflammation index in patients with post-traumatic stress disorder', *BMC Psychiatry*, 24, p. 966. Available at: <https://doi.org/10.1186/s12888-024-06439-y>

Zhang, S.-j., Xu, R.-y. and Kang, L.-l. (2024) 'Biomarkers for systemic lupus erythematosus: A scoping review', *Immunity, Inflammation and Disease*, 12, p. e70022. doi:10.1002/iid3.70022.